Neurochem, Inc. Falls on Poor Drug Outlook; Analyst Says Alzhemed May Fail Trial, Kiacta May Not Get FDA Approval

NEW YORK (AP) -- Shares of Canadian biotechnology company Neurochem Inc. fell Thursday after an analyst said the its drug candidate Alzhemed will likely fail in a late-stage clinical trial and Kiacta won’t receive Food and Drug Administration approval.